Open AccessFeature PaperArticle
Antiplasmodial Compounds from Deep-Water Marine Invertebrates
by
Amy E. Wright, Jennifer E. Collins, Bracken Roberts, Jill C. Roberts, Priscilla L. Winder, John K. Reed, Maria Cristina Diaz, Shirley A. Pomponi and Debopam Chakrabarti
Cited by 13 | Viewed by 3731
Abstract
Novel drug leads for malaria therapy are urgently needed because of the widespread emergence of resistance to all available drugs. Screening of the Harbor Branch enriched fraction library against the
Plasmodium falciparum chloroquine-resistant strain (Dd2) followed by bioassay-guided fractionation led to the identification
[...] Read more.
Novel drug leads for malaria therapy are urgently needed because of the widespread emergence of resistance to all available drugs. Screening of the Harbor Branch enriched fraction library against the
Plasmodium falciparum chloroquine-resistant strain (Dd2) followed by bioassay-guided fractionation led to the identification of two potent antiplasmodials; a novel diterpene designated as bebrycin A (
1) and the known C21 degraded terpene nitenin (
2). A SYBR Green I assay was used to establish a Dd2 EC
50 of 1.08 ± 0.21 and 0.29 ± 0.02 µM for bebrycin A and nitenin, respectively. Further analysis was then performed to assess the stage specificity of the inhibitors antiplasmodial effects on the Dd2 intraerythrocytic life cycle. Exposure to bebrycin A was found to block parasite maturation at the schizont stage if added any time prior to late schizogony at 42 hours post invasion, (HPI). In contrast, early life cycle exposure to nitenin (prior to 18 HPI) was identified as crucial to parasite inhibition, suggesting nitenin may target the maturation of the parasite during the transition from ring to early trophozoite (6–18 HPI), a novel property among known antimalarials.
Full article
►▼
Show Figures
